Pharmaceuticals News and Research

RSS

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Watson Pharmaceuticals receives FDA approval for generic Wellbutrin XL

Watson Pharmaceuticals, Inc. has announced that its subsidiary, Watson Laboratories, Inc., has received final approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets (XL) in the 150 mg strength.

26 Nov 2008

Sun Pharma acquires Chattem Chemicals, Inc

Sun Pharmaceutical Industries Ltd. has announced that its fully owned US subsidiary, Sun Pharmaceutical Industries, Inc., has acquired 100% ownership of Chattem Chemicals, Inc. (Chattem) from Elcat, Inc,.

26 Nov 2008

Misleading media coverage of clinical trials

Media coverage of clinical trials does not contain the elements readers require to make informed decisions.

26 Nov 2008

FDA issues complete response letter for Ceftobiprole for treatment of complicated skin infections

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

26 Nov 2008

Study looks at Tamiflu resistance in influenza viruses caused by environmental contamination

The research council FORMAS, Sweden, has granted 5.9 million SEK to a new research project that will study the environmental fate and effects of the anti-viral drug Tamiflu on the development on influenza resistance.

26 Nov 2008

Ceregene announces data from phase 2 clinical trial of CERE-120 for Parkinson's

Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease.

26 Nov 2008

Barr Labs confirms patent challenge of Amrix extended-release capsules

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix (cyclobenzaprine hydrochloride) extended-release capsules, 15mg and 30mg.

26 Nov 2008

Baffling chronic pain linked to rewiring of brain

Scientists peered at the brains of people with a baffling chronic pain condition and discovered something surprising.

26 Nov 2008

Researchers discover how brain cells can survive a stroke

Brain researchers at the University of Oslo in Norway have penetrated deeply into the innermost secrets of the brain to find out how brain cells can survive a stroke.

26 Nov 2008

Teva announces agreement on generic Pulmicort Respules patent challenge

Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort (Budesonide) Respules including all claims for patent infringement and damages.

25 Nov 2008

Roche to acquire Memory Pharmaceuticals

Roche and Memory Pharmaceuticals has announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million.

25 Nov 2008

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

Caraco Pharmaceutical Labs responds to FDA warning

Caraco Pharmaceutical Laboratories, Ltd. announced today that it has timely submitted its response to the FDA warning letter that was received on October 31, 2008.

25 Nov 2008

AstraZeneca settles U.S. Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals

AstraZeneca has announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA.

25 Nov 2008

Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Live oral Shigella vaccine licensed to PATH

The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries.

24 Nov 2008

Health problems associated with mineral oil contamination

From a quantitative standpoint, mineral oil is probably the largest contaminant of our body. That this contaminant can be tolerated without health concerns in humans has not been proven convincingly.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008